ViaCyte, Inc. is a stem cell engineering company dedicated to creating and commercializing cell therapies to treat diabetes. The company's goal is insulin independence without immunosuppression, hypoglycemia, or other diabetes-related complications.

Latest News

May 5, 2010
Novocell Becomes ViaCyte, Inc. as it Accelerates Pre-clinical Development of a Stem Cell Derived Treatment for Diabetes

May 5, 2010
ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes

October 28, 2009
Novocell is the Recipient of a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes

Device encapsulated stem cell-derived islet cells. In this image, insulin (INS, blue), glucagon (GCG, red) and somatostatin (SST, green) mark three of the five endocrine cells normally found in human islets.